WebNov 9, 2024 · The Investor Relations website contains information about DICE Therapeutics's business for stockholders, potential investors, and financial analysts. WebApr 11, 2024 · DICE Therapeutics, Inc. SEC Filing - Quarterly Report (10-Q) August 11, 2024 SEC Filings Thu, Aug. 11, 2024 DICE Therapeutics initiated at buy at Wainwright …
DICE THERAPEUTICS
WebApr 10, 2024 · According to 15 analysts, the average rating for DICE stock is "Buy." The 12-month stock price forecast is $63.97, which is an increase of 138.43% from the latest price. WebApr 6, 2024 · finance.yahoo.com - March 23 at 8:25 PM. Here’s Why Meridian Small Cap Growth Fund Trimmed DICE Therapeutics (DICE) finance.yahoo.com - March 22 at 8:21 AM. DICE Therapeutics (NASDAQ:DICE) Shares Down 6.8%. americanbankingnews.com - March 22 at 6:44 AM. Insider Selling: DICE Therapeutics, Inc. (NASDAQ:DICE) Director … my denver chart
10-Q - sec.gov
WebApr 1, 2024 · DICE Therapeutics Stock Performance. Shares of DICE opened at $28.67 on Friday. DICE Therapeutics has a 52-week low of $12.64 and a 52-week high of $45.99. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -13.40 and a beta of 0.71. The business's fifty day moving average is $29.47 and its 200-day moving average is … WebWe design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. We are developing a growing pipeline of high-impact oral therapeutic candidates. Our lead program targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases. WebMar 15, 2024 · R&D Expenses: Research and development expenses were $20.1 million and $62.6 million for the fourth quarter and full year ended December 31, 2024, respectively, as compared to $12.2 million and ... my deposit protection certificate